Study: Biomarkers could improve trials of Alzheimer's drugs

05/12/2009 | U.S. News & World Report

U.S. researchers found that measuring the levels of several biomarkers linked to Alzheimer's disease in the cerebrospinal fluid of patients with mild dementia might help predict the rate of their cognitive decline. The finding suggests that the biomarkers "might be useful as entry criteria for clinical trials of disease-modifying therapies for mild cognitive impairment and very mild dementia of the Alzheimer type," the researchers said.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD